- Home
- INMB vs ATYR Comparison
INMB vs ATYR Comparison
Compare INMB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ATYR
- Stock Information
- Founded
- INMB 2015
- ATYR 2005
- Country
- INMB United States
- ATYR United States
- Employees
- INMB N/A
- ATYR N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INMB Health Care
- ATYR Health Care
- Exchange
- INMB Nasdaq
- ATYR Nasdaq
- Market Cap
- INMB 49.2M
- ATYR 105.8M
- IPO Year
- INMB 2019
- ATYR 2015
- Fundamental
- Price
- INMB $1.90
- ATYR $1.01
- Analyst Decision
- INMB Buy
- ATYR Buy
- Analyst Count
- INMB 4
- ATYR 6
- Target Price
- INMB $9.53
- ATYR $8.88
- AVG Volume (30 Days)
- INMB 396.2K
- ATYR 12.3M
- Earning Date
- INMB 11-06-2025
- ATYR 11-06-2025
- Dividend Yield
- INMB N/A
- ATYR N/A
- EPS Growth
- INMB N/A
- ATYR N/A
- EPS
- INMB N/A
- ATYR N/A
- Revenue
- INMB $50,000.00
- ATYR N/A
- Revenue This Year
- INMB $191.43
- ATYR $420.85
- Revenue Next Year
- INMB $12,299.51
- ATYR $1,513.40
- P/E Ratio
- INMB N/A
- ATYR N/A
- Revenue Growth
- INMB N/A
- ATYR N/A
- 52 Week Low
- INMB $1.71
- ATYR $0.68
- 52 Week High
- INMB $11.64
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- INMB 43.14
- ATYR 32.00
- Support Level
- INMB $1.84
- ATYR $0.96
- Resistance Level
- INMB $1.95
- ATYR $1.10
- Average True Range (ATR)
- INMB 0.09
- ATYR 0.09
- MACD
- INMB 0.00
- ATYR 0.17
- Stochastic Oscillator
- INMB 29.40
- ATYR 75.58
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.